Employee No. 1: Doug Williams launches exosome R&D player Codiak Bio with $80M-plus

John Carroll

is now happy to reveal just why he stepped aside four months ago as R&D chief of Biogen. Last July, signed on as " number one" of BioSciences, which now has an $ 80 million-plus commitment from some prominent early-stage investors to launch a quest into the role exosomes can play in treating cancer and a wide variety of other diseases.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS